Sana Biotechnology Inc

The stock remains in a Stage 2 uptrend marked by clear higher highs and higher lows with rising EMAs. It is consolidating in the $3.80–$3.90 zone with neutral momentum and no exhaustion visible. EMAs are aligned bullishly, and the active Higher Highs & Higher Lows pattern supports continuation. Execution is deferred pending pullback acceptance into the 9/20EMA support or a breakout above the consolidation high. Key risks include a breakdown below the rising 20EMA and broader market weakness.

• ↑Initiating Phase 1/2 trials for SC451 (T1D) and SG293 (NHL) adds pipeline visibility
• ↑$25 M equity from Mayo Clinic validates technology and strengthens cash position
• ↓Q2 net loss of $63.6 M (versus $93.8 M prior year) highlights ongoing financial distress